NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
2.020
-0.180 (-8.18%)
At close: Jun 18, 2026, 4:00 PM EDT
2.120
+0.100 (4.95%)
After-hours: Jun 18, 2026, 5:23 PM EDT
NextCure Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
7.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNXTC News
- 1 day ago - NextCure Transcript: AGM 2026 - Transcripts
- 15 days ago - NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers - GlobeNewsWire
- 17 days ago - NextCure Transcript: KOL event - Transcripts
- 17 days ago - NextCure Press release: KOL event - Filings
- 17 days ago - NextCure Slides: KOL event - Filings
- 17 days ago - NextCure share weakness overdone, says Lucid Capital - TheFly
- 18 days ago - NextCure presents Phase 1 data for SIM0505 in gynecologic cancers - TheFly
- 18 days ago - NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 - GlobeNewsWire